NCT00486122已完成4 期
Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 282
- 试验地点
- 1
- 主要终点
- Test the hypothesis that atomoxetine administered orally, once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is superior to placebo in children with ADHD
研究概览
简要总结
The purpose of this study is to test the hypothesis that atomoxetine administered orally, once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is superior to placebo in children with ADHD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Years 至 12 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have ADHD that meets disease diagnostic criteria as defined by DSM-IV-Revised
- •Males or females who are at least 6 years old and no more than 12 years old prior to visit 2
- •Patients must be able to swallow capsules
- •Patients must be of normal intelligence in the judgment of the investigator. Normal intelligence is defined as being without evidence of significant general intellectual deficit and expected to achieve a score of 70 or more if formal IQ testing were administered.
- •Laboratory results must show no significant abnormalities (significance is defined as laboratory values requiring acute medical intervention, indicating a serious medical illness, or requiring further medical evaluation in the judgment of the investigator)
排除标准
- •Patients who weigh less than 20 kg or greater than 65 kg at study entry (visit 1)
- •Patients who have a documented history of bipolar I or bipolar II disorder, or psychosis
- •Patients who have documented autism, Asperger's syndrome, or pervasive developmental disorder.
- •Other comorbid psychiatric disorders are not excluded provided that the diagnosis of ADHD predates the comorbid disorder, and that the ADHD symptoms are the primary source of impairment for the patient
- •Patients taking any antipsychotic medication during the 4 weeks prior to visit 1 are not eligible.
结局指标
主要结局
Test the hypothesis that atomoxetine administered orally, once a day, at doses up to 1.4 mg/kg/day for approximately 6 weeks given in the morning is superior to placebo in children with ADHD
次要结局
- Test the hypothesis that atomoxetine administered once daily in the morning provides superior efficacy in the mornings (before daily dosing, i.e., nearly 24 hrs since last dosing) compared with placebo in children with ADHD based on the CGIP-M
- To assess the effect of dosing atomoxetine in the morning versus placebo on measures of executive functioning
- Test the hypothesis that atomoxetine administered once daily in the morning provides superior efficacy compared with placebo for measures of adaptive functioning in children with ADHD
- Test the hypothesis that atomoxetine administered once daily in the evening provides superior efficacy in the evenings (before daily dosing, i.e., nearly 24 hrs since last dosing) compared with placebo in children with ADHD
- Test the hypothesis that atomoxetine administered once daily in the morning provides superior efficacy in the mornings (before daily dosing, i.e., nearly 24 hrs since last dosing) compared with placebo in children with ADHD
- To examine the onset of action during the first week of treatment in the morning versus in the evening versus placebo
- To assess the effect of dosing atomoxetine in the evening versus placebo on measures of executive functioning
- To compare morning versus evening dosing versus placebo as assessed by the CGI-ADHD-S
- To assess the safety and tolerability of atomoxetine dosed in the morning versus in the evening versus placebo
- Test the hypothesis that atomoxetine administered once daily in the evening provides superior efficacy compared with placebo in children with ADHD
- Test the hypothesis that atomoxetine administered once daily in the morning provides superior efficacy in the evenings compared with placebo in children with ADHD
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Efficacy and Safety of Once-Daily Atomoxetine Hydrochloride in Adults With ADHD Over an Extended Period of Time (6 Months)ADHDNCT00190736Eli Lilly and Company440
已完成
4 期
Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional OutcomesAttention Deficit Hyperactivity DisorderNCT00510276Eli Lilly and Company445
已完成
4 期
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHDAttention-Deficit/Hyperactivity DisorderComorbid DyslexiaNCT00191048Eli Lilly and Company105
已完成
3 期
Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/AdolescentsAttention Deficit Hyperactivity DisorderNCT00191659Eli Lilly and Company200
终止
4 期
Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusECannabis AbuseAttention Deficit Hyperactivity DisorderNCT00687609Eli Lilly and Company7